^
    1year
    Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=69, Recruiting, MonTa Biosciences ApS | Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Apr 2023 --> Apr 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)
    |
    MBS8
    2years
    Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=69, Recruiting, MonTa Biosciences ApS | Trial completion date: Nov 2022 --> Apr 2023 | Trial primary completion date: Oct 2022 --> Apr 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)
    |
    MBS8
    over2years
    Systemic TLR7/8 micelles trigger a novel and potent anti-tumor response by strong recruitment of neutrophils leading to massive tumor cell killing. (ASCO 2022)
    Background: Clinical use of TLR7/8 agonists is currently restricted to topical application of Imiquimod for treatment of superficial basal cell carcinoma since systemic administration is prevented due to dose-limiting toxicity. MBS8 showed significant anti-cancer activity in multiple in vivo solid tumor models when administered either as monotherapy or in combination with ICIs. MBS8 demonstrated a novel mode of action with neutrophils playing a central role as primary effector cells causing a rapid killing of tumors. Further, adaptive immune response was initiated including generation of tumor specific CD8+ cells and establishment of the immune memory.
    PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • TLR7 (Toll Like Receptor 7)
    |
    Zyclara (imiquimod) • MBS8
    over3years
    Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=69, Recruiting, MonTa Biosciences ApS
    Clinical • New P1 trial
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)
    |
    MBS8